Dan Elbaum

Company: QurAlis Corp.

Job title: Chief Scientific Officer

Seminars:

Exploring a Splice Modulation Antisense Oligonucleotide to Restore STATHMIN-2 Levels in ALS Patients 11:00 am

• A splice modulation ASO strategy with the aim to treat 90% of the total ALS population (TDP-43 positive patients) • Optimizing dosage to ensure efficacious and safe therapeutic output • Biomarker strategies to evaluate target engagement and efficacy for STMN2 ASO trialsRead more

day: Day Two AM

Panel Discussion: Evaluating Current Strategies for ALS Target Identification: What are the Avenues to Still Prioritise? 10:30 am

Outlining current avenues of disease pathology to identify and validate targets for familial and sporadic ALS Processing disease pathology information to validate genetic ALS targets Where are the current innovations for novel target identification?Read more

day: Day One AM